These products are not intended to diagnose, treat, cure or prevent any disease
Even if these approaches are successful in many cases, there is still a subset (3%5% of patients) that progress to therapeutically refractive disease, constituting the so-called TC-related deaths due to the lack of effective treatment. In this view, some efforts are ongoing to identify personalized therapy for refractory patients and drug repositioning represents one of the potential alternatives (Xu et al., 2019)
[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Coleman M., Blass J.P
As such, the answer to this question pertains to everything from a patients decision to use a GLP-1 medication or a providers likelihood of prescribing one, to health plans and employers coverage decisions, and investment strategies for companies ranging from consumer products to pharma
I.NuberS.et al (2019)
By reading this article, you acknowledge agreement with this disclaimer